Skip to main content

A practical approach to normocalcemic primary hyperparathyroidism

Abstract

Normocalcemic primary hyperparathyroidism is an entity on which several issues about its clinical management remains unclear. This is reflected in the main current guidelines, where there are no evidence-based specific recommendations. Through an exhaustive review of current literature, a clinical management algorithm for these patients is proposed. We consider the diagnosis criteria, the differential diagnosis, the clinical manifestations, and the treatment indications. When indicated, we also review the preoperative locations techniques and the surgical approach. Finally, when surgical treatment is not indicated, the patient is not a candidate to surgery or refuse surgical management, we review the medical treatment options and the follow-up schemes.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. J.P. Bilezikian, A.A. Khan, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009). https://doi.org/10.1210/jc.2008-1763

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. N.E. Cusano, S.J. Silverberg, J.P. Bilezikian, Normocalcemic primary hyperparathyroidism. J. Clin. Densitom. 16, 33–39 (2013). https://doi.org/10.1016/j.jocd.2012.12.001

    Article  PubMed  PubMed Central  Google Scholar 

  3. J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014). https://doi.org/10.1210/jc.2014-1413

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. S.M. Wilhelm, T.S. Wang, D.T. Ruan, J.A. Lee, S.L. Asa, Q.Y. Duh, G.M. Doherty, M.F. Herrera, J.L. Pasieka, N.D. Perrier, S.J. Silverberg, C.C. Solórzano, C. Sturgeon, M.E. Tublin, R. Udelsman, S.E. Carty, The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 151, 959–968 (2016). https://doi.org/10.1001/jamasurg.2016.2310

    Article  PubMed  Google Scholar 

  5. R. Eastell, M.L. Brandi, A.G. Costa, P. D’Amour, D.M. Shoback, R. Thakker, V: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3570–3579 (2014). https://doi.org/10.1210/jc.2014-1414

    CAS  Article  PubMed  Google Scholar 

  6. M. Schini, R.M. Jacques, E. Oakes, N.F.A. Peel, J.S. Walsh, R. Eastell, Normocalcemic hyperparathyroidism: Study of its prevalence and natural history. J. Clin. Endocrinol. Metab. 105, E1171–E1186 (2020). https://doi.org/10.1210/clinem/dgaa084

    Article  PubMed Central  Google Scholar 

  7. J.F. Aloia, M. Feuerman, J.K. Yeh, Reference range for serum parathyroid hormone. Endocr. Pract. 12, 137–144 (2006). https://doi.org/10.4158/EP.12.2.137

    Article  PubMed  PubMed Central  Google Scholar 

  8. C.-J.L. Farrell, L. Nguyen, A.C. Carter, Parathyroid hormone: data mining for age-related reference intervals in adults. Clin. Endocrinol. (Oxf.). 88, 311–317 (2018). https://doi.org/10.1111/cen.13486

    CAS  Article  PubMed  Google Scholar 

  9. J.A. Delgado, J.M. Bauça, M.I. Pastor, A. Barceló, Use of data mining in the establishment of age-adjusted reference intervals for parathyroid hormone. Clin. Chim. Acta 508, 217–220 (2020). https://doi.org/10.1016/j.cca.2020.05.030

    CAS  Article  PubMed  Google Scholar 

  10. N.B. Dawood, K.L. Yan, A. Shieh, M.J. Livhits, M.W. Yeh, A.M. Leung, Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges. Clin. Endocrinol. (Oxf.). 93, 519–527 (2020). https://doi.org/10.1111/cen.14315

    CAS  Article  PubMed  Google Scholar 

  11. J. Gómez-Ramírez, A. Gómez-Valdazo, P. Luengo, B. Porrero, I. Osorio, S. Rivas, Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? Am. J. Surg. 219, 150–153 (2020). https://doi.org/10.1016/j.amjsurg.2019.10.032

    Article  PubMed  Google Scholar 

  12. L.M. Calvi, D.A. Bushinsky, When is it appropriate to order an ionized calcium? J. Am. Soc. Nephrol. 19, 1257–1260 (2008). https://doi.org/10.1681/ASN.2007121327

    CAS  Article  PubMed  Google Scholar 

  13. S. Corbetta, Normocalcemic Hyperparathyroidism. Front. Horm. Res. 51, 23–39 (2019). https://doi.org/10.1159/000491036

    CAS  Article  PubMed  Google Scholar 

  14. G. Zavatta, B.L. Clarke, Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed? JBMR 4, e10391 (2020). https://doi.org/10.1002/jbm4.10391

    Article  Google Scholar 

  15. A. Giustina, R. Bouillon, N. Binkley, C. Sempos, R.A. Adler, J. Bollerslev, B. Dawson-Hughes, P.R. Ebeling, D. Feldman, A. Heijboer, G. Jones, C.S. Kovacs, M. Lazaretti-Castro, P. Lips, C. Marcocci, S. Minisola, N. Napoli, R. Rizzoli, R. Scragg, J.H. White, A.M. Formenti, J.P. Bilezikian, C. Labrador, Controversies in Vitamin D: A Statement From the Third International Conference. JBMR . 4, e10417 (2020). https://doi.org/10.1002/jbm4.10417

    Article  Google Scholar 

  16. C. Cipriani, J. Pepe, L. Colangelo, S. Minisola, Vitamin D and Secondary Hyperparathyroid States. Front. Horm. Res. 50, 138–148 (2018). https://doi.org/10.1159/000486077

    CAS  Article  PubMed  Google Scholar 

  17. A. Palermo, A.M. Naciu, G. Tabacco, S. Falcone, A. Santonati, D. Maggi, L.D.’ Onofrio, S.I. Briganti, D. Castellitto, A. Casini, C. Pedone, D. Lelli, A. Fabbri, J.P. Bilezikian, N. Napoli, P. Pozzilli, S. Manfrini, R. Cesareo, Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 105, 2609–2616 (2020). https://doi.org/10.1210/clinem/dgaa174

    Article  Google Scholar 

  18. B.C. Silva, N.E. Cusano, J.P. Bilezikian, Primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 101247 (2018). https://doi.org/10.1016/j.beem.2018.09.013

  19. X. Wang, L. Meng, C. Su, S.A. Shapses, Low free (but not total) 25-hydroxyvitamin D levels in subjects with normocalcemic hyperparathyroidism. Endocr. Pract. 26, 174–178 (2020). https://doi.org/10.4158/EP-2019-0325

    Article  PubMed  Google Scholar 

  20. N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best. Pract. Res. Clin. Endocrinol. Metab. 32, 837–845 (2018). https://doi.org/10.1016/j.beem.2018.09.009

    Article  PubMed  Google Scholar 

  21. J. Gómez-Ramírez, R. Mihai, Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm. Langenbeck’s Arch. Surg. 402, 1103–1108 (2017). https://doi.org/10.1007/s00423-017-1617-2

    Article  Google Scholar 

  22. C. Eller-Vainicher, E. Cairoli, V.V. Zhukouskaya, V. Morelli, S. Palmieri, A. Scillitani, P. Beck-Peccoz, I. Chiodini, Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. Eur. J. Endocrinol. 169, 225–237 (2013). https://doi.org/10.1530/EJE-13-0102

    CAS  Article  PubMed  Google Scholar 

  23. G. Martínez Díaz-Guerra, E. Jódar Gimeno, R. Reyes García, J.M. Gómez Sáez, M. Muñoz-Torres, Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up. Endocrinol. Nutr. 60, 456–.e1–6 (2013). https://doi.org/10.1016/j.endonu.2013.01.015

  24. B.H. Eisner, J. Ahn, M.L. Stoller, Differentiating primary from secondary hyperparathyroidism in stone patients: the “thiazide challenge”. J. Endourol. 23, 191–192 (2009). https://doi.org/10.1089/end.2008.0567

    Article  PubMed  Google Scholar 

  25. M.L. Griebeler, A.E. Kearns, E. Ryu, P. Thapa, M.A. Hathcock, L.J. Melton, R.A. Wermers, Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J. Clin. Endocrinol. Metab. 101, 1166–1173 (2016). https://doi.org/10.1210/jc.2015-3964

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. G. Mantovani, M. Bastepe, Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat. Rev. Endocrinol. 47, 41. https://doi.org/10.1038/s41574-018-0042-0

  27. D.A. Anastasilakis, P. Makras, S.A. Polyzos, A.D. Anastasilakis, Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones 18, 65–70 (2019). https://doi.org/10.1007/s42000-018-0069-6

    Article  PubMed  Google Scholar 

  28. M.M. Tuna, M. Çalışkan, M. Ünal, T. Demirci, B.A. Doğan, K. Küçükler, M. Özbek, D. Berker, T. Delibaşı, S. Güler, Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Miner. Metab. 34, 331–335 (2016). https://doi.org/10.1007/s00774-015-0673-3

    CAS  Article  PubMed  Google Scholar 

  29. E. Traini, R. Bellantone, S.E. Tempera, S. Russo, C. De Crea, C.P. Lombardi, M. Raffaelli, Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? Langenbeck’s Arch. Surg. 403, 317–323 (2018). https://doi.org/10.1007/s00423-018-1659-0

    Article  Google Scholar 

  30. C. Berger, O. Almohareb, L. Langsetmo, D.A. Hanley, C.S. Kovacs, R.G. Josse, J.D. Adachi, J.C. Prior, T. Towheed, K.S. Davison, S.M. Kaiser, J.P. Brown, D. Goltzman, Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin. Endocrinol. (Oxf.). 82, 359–368 (2015). https://doi.org/10.1111/cen.12569

    CAS  Article  PubMed  Google Scholar 

  31. L. Rejnmark, H. Ejlsmark-Svensson, Effects of PTH and PTH hypersecretion on bone: a clinical perspective. Curr. Osteoporos. Rep. 18, 103–114 (2020). https://doi.org/10.1007/s11914-020-00574-7

    Article  PubMed  Google Scholar 

  32. A.M. Formenti, F. Tecilazich, R. Giubbini, A. Giustina, Risk of vertebral fractures in hypoparathyroidism. Rev. Endocr. Metab. Disord. 20, 295–302 (2019). https://doi.org/10.1007/s11154-019-09507-x

    CAS  Article  PubMed  Google Scholar 

  33. A.M. Naciu, G. Tabacco, S. Falcone, G.G. Incognito, I. Chiodini, D. Maggi, C. Pedone, D. Lelli, J.P. Bilezikian, N. Napoli, S. Manfrini, R. Cesareo, A. Palermo, Bone quality, as measured by trabecular bone score in normocalcaemic primary hyperparathyroidism. Endocr. Pract. (2021). https://doi.org/10.1016/j.eprac.2021.04.884

  34. G. Díaz-Soto, D. de Luis Román, O.I. Jauregui, L. Briongo, E. Romero, J.L. Pérez-Castrillón, Trabecular bone score in patients with normocalcemic hyperparathyroidism. Endocr. Pract. 22, 703–707 (2016). https://doi.org/10.4158/EP151055.OR

    Article  PubMed  Google Scholar 

  35. G.B. Cansu, N. Yilmaz, S. Özdem, M.K. Balci, G. Süleymanlar, C. Arici, A. Boz, R. Sari, H.A. Altunbaş, Parathyroidectomy in asymptomatic primary hyperparathyroidism reduces carotid intima-media thickness and arterial stiffness. Clin. Endocrinol. (Oxf.). 84, 39–47 (2016). https://doi.org/10.1111/cen.12952

    CAS  Article  PubMed  Google Scholar 

  36. A.J. van Ballegooijen, I. Reinders, M. Visser, I.A. Brouwer, Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am. Heart J. 165, 655–664 (2013). https://doi.org/10.1016/j.ahj.2013.02.014. 664.e1–5

    CAS  Article  PubMed  Google Scholar 

  37. G. Chen, Y. Xue, Q. Zhang, T. Xue, J. Yao, H. Huang, J. Liang, L. Li, W. Lin, L. Lin, L. Shi, L. Cai, J. Wen, Is normocalcemic primary hyperparathyroidism harmful or harmless? J. Clin. Endocrinol. Metab. 100, 2420–2424 (2015). https://doi.org/10.1210/jc.2014-4432

    CAS  Article  PubMed  Google Scholar 

  38. F.Y. Ozturk, S. Erol, M.M. Canat, S. Karatas, I. Kuzu, S.D. Cakir, Y. Altuntas, Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr. J. 63, 111–118 (2016). https://doi.org/10.1507/endocrj.EJ15-0392

    CAS  Article  Google Scholar 

  39. S. Beysel, M. Caliskan, M. Kizilgul, M. Apaydin, S. Kan, M. Ozbek, E. Cakal, Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc. Disord. 19, 1–8 (2019). https://doi.org/10.1186/s12872-019-1093-4

    CAS  Article  Google Scholar 

  40. O. Koubaity, D. Mandry, P.L. Nguyen-Thi, F. Bihain, C. Nomine-Criqui, L. Demarquet, V. Croise-Laurent, L. Brunaud, Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery 167, 149–154 (2020). https://doi.org/10.1016/j.surg.2019.05.094

    Article  PubMed  Google Scholar 

  41. S. Temizkan, O. Kocak, K. Aydin, A. Ozderya, G. Arslan, N. Yucel, M. Sargin, Normocalcemic hyperparathyroidism and insulin resistance. Endocr. Pract. 21, 23–29 (2015). https://doi.org/10.4158/EP14195.OR

    Article  PubMed  Google Scholar 

  42. P.N. Mesquita, A.P.D.L. Leite, S. Crisóstomo, C. das, E.V. Filho, L. Da Cunha Xavier, F. Bandeira, Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc. Health Risk Manag 13, 225–229 (2017). https://doi.org/10.2147/VHRM.S128084

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. L.S. Bislev, L. Langagergaard Rødbro, T. Sikjær, L. Rejnmark, Effects of elevated parathyroid hormone levels on muscle health, postural stability and quality of life in vitamin D-insufficient healthy women: a cross-sectional study. Calcif. Tissue Int. 105, 642–650 (2019). https://doi.org/10.1007/s00223-019-00612-2

    CAS  Article  PubMed  Google Scholar 

  44. L. Voss, M. Nóbrega, L. Bandeira, L. Griz, P.A.S. Rocha-Filho, F. Bandeira, Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism. Bone 141, 115583 (2020). https://doi.org/10.1016/j.bone.2020.115583

    CAS  Article  PubMed  Google Scholar 

  45. H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007). https://doi.org/10.1210/jc.2006-2802

    CAS  Article  PubMed  Google Scholar 

  46. H. Šiprová, Z. Fryšák, M. Souček, Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr. Pract. 22, 294–301 (2016). https://doi.org/10.4158/EP15704.OR

    Article  PubMed  Google Scholar 

  47. H. Yan, N. Calcatera, T.A. Moo-Young, R.A. Prinz, D.J. Winchester, Degree of hypercalcemia correlates with parathyroidectomy but not with symptoms. Am. J. Surg. 217, 437–440 (2019). https://doi.org/10.1016/j.amjsurg.2018.09.010

    Article  PubMed  Google Scholar 

  48. J.Y. Lim, M.C. Herman, L. Bubis, I. Epelboym, J.D. Allendorf, J.A. Chabot, J.A. Lee, J.H. Kuo, Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161, 70–77 (2017). https://doi.org/10.1016/j.surg.2016.08.054

    Article  PubMed  Google Scholar 

  49. G. Trinh, E. Rettig, S.I. Noureldine, J.O. Russell, N. Agrawal, A. Mathur, J.D. Prescott, M.A. Zeiger, R.P. Tufano, Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome. Otolaryngol. Head. Neck Surg. 159, 630–637 (2018). https://doi.org/10.1177/0194599818793879

    Article  PubMed  Google Scholar 

  50. A. Kiriakopoulos, A. Petralias, D. Linos, Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ? World J. Surg. 42, 992–997 (2018). https://doi.org/10.1007/s00268-018-4512-2

    Article  PubMed  Google Scholar 

  51. C.E. Graves, C.M. McManus, J.A. Chabot, J.A. Lee, J.H. Kuo, Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism. World J. Surg. 44, 488–495 (2020). https://doi.org/10.1007/s00268-019-05157-x

    Article  PubMed  Google Scholar 

  52. F. Tassone, A. Guarnieri, E. Castellano, C. Baffoni, R. Attanasio, G. Borretta, Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 100, 3069–3073 (2015). https://doi.org/10.1210/jc.2015-2132

    CAS  Article  PubMed  Google Scholar 

  53. K. Lundstam, A. Heck, K. Godang, C. Mollerup, M. Baranowski, Y. Pernow, T. Aas, O. Hessman, T. Rosén, J. Nordenström, S. Jansson, M. Hellström, J. Bollerslev, Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J. Bone Miner. Res. 32, 1907–1914 (2017). https://doi.org/10.1002/jbmr.3177

    Article  PubMed  Google Scholar 

  54. S.P. Cheng, J.J. Lee, T.P. Liu, P.S. Yang, S.C. Liu, Y.C. Hsu, C.L. Liu, Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: a meta-analysis of randomized controlled trials. Med. (Baltim.) 94, e931 (2015). https://doi.org/10.1097/MD.0000000000000931

    Article  Google Scholar 

  55. S. Sho, E.J. Kuo, A.C. Chen, N. Li, M.W. Yeh, M.J. Livhits, Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism. Ann. Surg. Oncol. 26, 539–546 (2019). https://doi.org/10.1245/s10434-018-6998-0

    Article  PubMed  Google Scholar 

  56. D. Lee, M.D. Walker, H.Y. Chen, J.A. Chabot, J.A. Lee, J.H. Kuo, Bone mineral density changes after parathyroidectomy are dependent on biochemical profile. Surgery 165, 107–113 (2019). https://doi.org/10.1016/j.surg.2018.04.065

    Article  PubMed  Google Scholar 

  57. J. Pepe, C. Cipriani, C. Sonato, O. Raimo, F. Biamonte, S. Minisola, Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur. J. Endocrinol. 177, R297–R308 (2017). https://doi.org/10.1530/EJE-17-0485

    CAS  Article  PubMed  Google Scholar 

  58. C. Blanchard, M. Mathonnet, F. Sebag, C. Caillard, C. Kubis, D. Drui, E. van Nuvel, C. Ansquer, J.F. Henry, D. Masson, F. Kraeber-Bodéré, J.B. Hardouin, R. Zarnegar, A. Hamy, E. Mirallié, Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann. Surg. Oncol. 21, 3534–3540 (2014). https://doi.org/10.1245/s10434-014-3731-5

    Article  PubMed  Google Scholar 

  59. S. Bannani, N. Christou, C. Guérin, A. Hamy, F. Sebag, M. Mathonnet, P. Guillot, C. Caillard, C. Blanchard, E. Mirallié, Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br. J. Surg. 105, 223–229 (2018). https://doi.org/10.1002/bjs.10739

    CAS  Article  PubMed  Google Scholar 

  60. P. Cunha-Bezerra, R. Vieira, F. Amaral, H. Cartaxo, T. Lima, U. Montarroyos, F. Bandeira, Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. J. Med. Imaging Radiat. Oncol. 62, 493–498 (2018). https://doi.org/10.1111/1754-9485.12728

    Article  Google Scholar 

  61. H. Mazeh, H. Chen, G. Leverson, R.S. Sippel, Creation of a “Wisconsin index” nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann. Surg. 257, 138–141 (2013). https://doi.org/10.1097/SLA.0b013e31825ffbe1

    Article  PubMed  Google Scholar 

  62. E. Trébouet, S. Bannani, M. Wargny, C. Leux, C. Caillard, F. Kraeber-Bodéré, K. Renaudin, L. Chaillous, É. Mirallié, C. Ansquer, Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate. Langenbeck’s Arch. Surg. 404, 431–438 (2019). https://doi.org/10.1007/s00423-019-01782-1

    Article  Google Scholar 

  63. T.K. Pandian, C.C. Lubitz, S.H. Bird, L.E. Kuo, A.E. Stephen, Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis. Surgery 167, 168–172 (2020). https://doi.org/10.1016/j.surg.2019.06.043

    CAS  Article  PubMed  Google Scholar 

  64. I. Bossert, S. Chytiris, M. Hodolic, L. Croce, L. Mansi, L. Chiovato, G. Mariani, G. Trifirò, PETC/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J. Endocrinol. Invest. 42, 419–426 (2019). https://doi.org/10.1007/s40618-018-0931-z

    CAS  Article  PubMed  Google Scholar 

  65. D.M. Carneiro, C.C. Solorzano, M.C. Nader, M. Ramirez, G.L. Irvin, 3rd: Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 134, 973–981 (2003). https://doi.org/10.1016/j.surg.2003.06.001

    Article  PubMed  Google Scholar 

  66. T.J. Wade, T.W.F. Yen, A.L. Amin, T.S. Wang, Surgical management of normocalcemic primary hyperparathyroidism. World J. Surg. 36, 761–766 (2012). https://doi.org/10.1007/s00268-012-1438-y

    Article  PubMed  Google Scholar 

  67. M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115–125 (2018). https://doi.org/10.1038/nrendo.2017.104

    CAS  Article  PubMed  Google Scholar 

  68. B. Farford, R.J. Presutti, T.J. Moraghan, Nonsurgical management of primary hyperparathyroidism. Mayo Clin. Proc. 82, 351–355 (2007). https://doi.org/10.4065/82.3.351

    Article  PubMed  Google Scholar 

  69. M.T. Drake, B.L. Clarke, S. Khosla, Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032–1045 (2008). https://doi.org/10.4065/83.9.1032

    CAS  Article  PubMed  Google Scholar 

  70. A.A. Khan, J.P. Bilezikian, A.W.C. Kung, M.M. Ahmed, S.J. Dubois, A.Y.Y. Ho, D. Schussheim, M.R. Rubin, A.M. Shaikh, S.J. Silverberg, T.I. Standish, Z. Syed, Z.A. Syed, Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 3319–3325 (2004). https://doi.org/10.1210/jc.2003-030908

    CAS  Article  PubMed  Google Scholar 

  71. R. Cesareo, E. Di Stasio, F. Vescini, G. Campagna, R. Cianni, V. Pasqualini, F. Romitelli, F. Grimaldi, S. Manfrini, A. Palermo, Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos. Int. 26, 1295–1302 (2015). https://doi.org/10.1007/s00198-014-3000-2

    CAS  Article  PubMed  Google Scholar 

  72. G. Tsvetov, D. Hirsch, I. Shimon, C. Benbassat, H. Masri-Iraqi, A. Gorshtein, D. Herzberg, T. Shochat, I. Shraga-Slutzky, T. Diker-Cohen, Thiazide treatment in primary hyperparathyroidism-a new indication for an old medication? J. Clin. Endocrinol. Metab. 102, 1270–1276 (2017). https://doi.org/10.1210/jc.2016-2481

    Article  PubMed  Google Scholar 

  73. S. Brardi, G. Cevenini, T. Verdacchi, G. Romano, R. Ponchietti, Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch. Ital. di Urol. Androl. 87, 66–71 (2015). https://doi.org/10.4081/aiua.2015.1.66

    CAS  Article  Google Scholar 

Download references

Author contributions

Conceptualization, J.L.M.N. and M.M.A.; literature review and writing—original draft preparation, J.L.M.N., M.S.N. and I.H.M.; writing—review and editing, J.L.M.N., M.S.N., I.H.M. and M.M.A.; supervision, J.L.M.N. and M.M.A. All authors have read and agreed to the published version of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mónica Marazuela Azpiroz.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Muñoz de Nova, J.L., Sampedro-Nuñez, M., Huguet-Moreno, I. et al. A practical approach to normocalcemic primary hyperparathyroidism. Endocrine 74, 235–244 (2021). https://doi.org/10.1007/s12020-021-02845-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-021-02845-4

Keywords

  • Hyperparathyroidism
  • Normocalcemic
  • Parathyroidectomy
  • Parathyroid hormone